We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System
News

StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System

StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System
News

StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "StemCor Systems Receives FDA Clearance for Bone Marrow Harvesting System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

StemCor Systems, Inc. has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its MarrowMiner™ for the harvest of bone marrow.

"Regulatory clearance of StemCor's MarrowMiner is a major accomplishment for the Company as we develop the necessary tools to extract, process and deliver bone marrow-derived adult stem and progenitor cells," said Vartan Ghazarossian, PhD, President and CEO of StemCor Systems.

"The MarrowMiner is the first minimally-invasive system for the collection of bone marrow, making marrow extraction faster, safer and more comfortable. Physicians will now be able to use this system to collect marrow from healthy donors for bone marrow transplantation, as well as from patients who are to be treated with their own marrow-derived cells, for an expanding array of current and emerging regenerative medicine applications."

"We believe this novel and innovative system addresses a large unmet clinical need to gain access to sufficient adult-bone marrow derived cells in a safe, convenient and reliable manner," said Paul Yock, MD, Weiland Professor of Medicine and Bioengineering and Director, Program in Biodesign, Stanford University.

"This technology meets a key need to access a patient's own cells for use in treating a variety of diseases and conditions."

Advertisement